Related Experiment Video
Updated: Jul 2, 2026
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
Shugan Xiaozhi decoction protects mice against metabolic dysfunction associated steatohepatitis by modulating liver
Shuai Wang1, Xiaohui Wang2, Jianxing Gao3
1Department of Hepatology, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, No. 15, Yingchun Road, Luohu District, Guangdong 518033, China; Shenzhen Key Laboratory of Liver Diseases of Chinese Medicine, No. 15, Yingchun Road, Luohu District, Guangdong 518033, China; Faculty of Chinese Medicine and State Key Laboratory of Mechanism and Quality of Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau 999078, China.
Abstract:
Metabolic dysfunction associated steatohepatitis (MASH) is a pathological change of the liver that poses a major public safety challenge. Shugan Xiaozhi (SGXZ) decoction is specially developed for MASH. This study seeks to investigate whether SGXZ decoction could ameliorate MASH in vivo and its mechanism from the perspectives of intestinal flora. Through chemical analysis of SGXZ decoction, 30 effective components were initially obtained. The results of pathological and biochemical indexes analysis indicated that SGXZ decoction could effectively regulate the pathological state of MASH mice. It was manifested by the improvement of hepatic steatosis, inflammation, and lipid accumulation. The intestinal flora of MASH mice was significantly different from that of the control group in terms of diversity and richness. After SGXZ decoction intervention, the diversity and richness of intestinal flora in MASH mice returned to close to the control level. Moreover, SGXZ decoction intervention increased the abundance of beneficial bacteria (such as Bifidobacterium) and decreased the abundance of pathogenic bacteria (such as Bacillus cereus) in MASH. In addition, SGXZ decoction restored the expressions of intestinal tight junction proteins, including zonula occludens-1 (ZO-1), claudin-1 and occludin, and activated the farnesoid X receptor (FXR)-fibroblast growth factor 15 (FGF15) pathway in the intestine. Our results implied that SGXZ decoction could effectively alleviate MASH, and its mechanism included regulating intestinal flora, maintaining intestinal barrier function, activating FXR-FGF15 pathway, and improving liver injury and liver fat accumulation.
